Altimmune, Inc. (ALT): who owns it and who trades it
As of Nov 16, 2026, ALT insiders reported 14 purchases worth $452K in the last 12 months. The largest buyer was Jerome Benedict Durso (Director), with $263K. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Altimmune
From the latest filingsOverall: more buying than selling. Funds, insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ALT
210 funds and institutions reported ALT shares worth $463M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 15.7%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 20.39M | 15.67% | $62M | +59% |
| Deep Track Capital, LP | 19.25M | 14.80% | $58.5M | – |
| State Street Corp | 12.10M | 9.30% | $36.8M | +69% |
| TCG Crossover Management, LLC | 10.00M | 7.69% | $30.4M | – |
| Vanguard Capital Management LLC | 8.18M | 6.29% | $24.9M | +45% |
| Vanguard Portfolio Management LLC | 7.33M | 5.64% | $22.3M | +36% |
| Marshall Wace, LLP | 6.84M | 5.26% | $20.8M | +70% |
| Viking Global Investors LP | 6.70M | 5.15% | $20.4M | – |
| Ra Capital Management, L.P. | 6.50M | 5.00% | $19.8M | – |
| Geode Capital Management, LLC | 5.01M | 3.85% | $15.2M | +61% |
| Woodline Partners LP | 3.40M | 2.61% | $10.3M | – |
| Millennium Management LLC | 3.31M | 2.54% | $10.1M | +2% |
| Nantahala Capital Management, LLC | 3.00M | 2.31% | $9.1M | – |
| Trails Edge Capital Partners, LP | 2.66M | 2.05% | $8.1M | – |
| Nuveen, LLC | 2.41M | 1.85% | $7.3M | +3% |
| Two Sigma Investments, LP | 2.38M | 1.83% | $7.2M | -4% |
| Goldman Sachs Group Inc | 2.21M | 1.70% | $6.7M | +64% |
| Great Point Partners LLC | 1.74M | 1.34% | $5.3M | – |
| Northern Trust Corp | 1.60M | 1.23% | $4.9M | +60% |
| Weiss Asset Management LP | 1.53M | 1.18% | $4.7M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ALT insiders reported $452K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Gregory L Weaver | CFO | Purchase | 10,000 | $1.62 | $16.2K | Form 4 |
| Nov 13, 2026 | Jerome Benedict Durso | CEO | Purchase | 30,700 | $1.62 | $49.7K | Form 4 |
| Nov 13, 2026 | Wayne Pisano | Director | Purchase | 10,000 | $1.64 | $16.4K | Form 4 |
| Aug 13, 2026 | Jerome Benedict Durso | CEO | Purchase | 15,000 | $2.95 | $44.2K | Form 4 |
| Apr 6, 2026 | John Gill | Director | Purchase | 9,200 | $3.41 | $31.4K | Form 4 |
| Apr 1, 2026 | Gregory L Weaver | CFO | Purchase | 10,000 | $3.15 | $31.5K | Form 4 |
| Apr 1, 2026 | Jerome Benedict Durso | CEO | Purchase | 15,000 | $3.14 | $47.1K | Form 4 |
| Mar 6, 2026 | Gregory L Weaver | CFO | Purchase | 5,000 | $3.54 | $17.7K | Form 4 |
| Mar 6, 2026 | Jerome Benedict Durso | CEO | Purchase | 20,000 | $3.54 | $70.8K | Form 4 |
| Jan 8, 2026 | Wayne Pisano | Director | Purchase | 5,000 | $4.08 | $20.4K | Form 4 |
| Jan 5, 2026 | Catherine A. Sohn | Director | Purchase | 500 | $4.24 | $2.1K | Form 4 |
| Dec 29, 2025 | Diane Jorkasky | Director | Purchase | 527 | $3.80 | $2K | Form 4 |
| Dec 23, 2025 | John Gill | Director | Purchase | 12,500 | $4.10 | $51.2K | Form 4 |
| Dec 22, 2025 | Jerome Benedict Durso | Director | Purchase | 12,500 | $4.13 | $51.6K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jerome Benedict Durso | Director | $263K | – | Nov 13, 2026 |
| John Gill | Director | $82.6K | – | Apr 6, 2026 |
| Gregory L Weaver | Chief Financial Officer | $65.4K | – | Nov 13, 2026 |
| Wayne Pisano | Director | $36.8K | – | Nov 13, 2026 |
| Catherine A. Sohn | Director | $2.1K | – | Jan 5, 2026 |
| Diane Jorkasky | Director | $2K | – | Dec 29, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ALT short interest
Very high short interest. 21.7% of ALT shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 12%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 42.13M ALT shares were sold short, 21.7% of the shares outstanding, down 0.2% from the report before. At the average daily volume of 3.46M shares, buying them all back would take about 12.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 42.13M | 21.66% | -0% | 3.46M | 12.2 |
| Oct 15, 2026 | 42.23M | 21.71% | -8% | 4.05M | 10.4 |
| Sep 30, 2026 | 46.08M | 23.69% | -11% | 4.37M | 10.5 |
| Sep 15, 2026 | 51.75M | 26.60% | +4% | 3.37M | 15.4 |
| Aug 31, 2026 | 49.71M | 25.56% | -2% | 4.20M | 11.8 |
| Aug 14, 2026 | 50.97M | 26.20% | -2% | 4.62M | 11.0 |
| Jul 31, 2026 | 51.94M | 39.93% | +8% | 4.53M | 11.4 |
| Jul 15, 2026 | 48.24M | 37.09% | +1% | 3.85M | 12.5 |
| Jun 30, 2026 | 47.63M | 36.62% | +14% | 5.90M | 8.1 |
| Jun 15, 2026 | 41.93M | 32.23% | +7% | 2.88M | 14.6 |
| May 29, 2026 | 39.12M | 30.08% | +4% | 2.70M | 14.5 |
| May 15, 2026 | 37.64M | 28.94% | +6% | 3.42M | 11.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Altimmune company events
Altimmune filed 14 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 29, 2026.
- Oct 29, 2026DebtTook on new debt. Filing
- Oct 27, 2026LeadershipThe Board of Directors, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Peter Greenleaf and Alex Howarth as directors of the Board effective November 2, 2026, and approved an increase in its size from nine to eleven directors. Filing
- Sep 29, 2026LeadershipThe Board of Directors of Altimmune, Inc. appointed Richard Menziuso as the Company’s Vice President, Global Controller and Principal Accounting Officer effective as of September 29, 2026. Filing
- Aug 12, 2026ResultsReleased financial results. Filing
- Jul 28, 2026AnnouncementAs noted above, on July 28, 2026, the Company announced the positive topline results from the RECLAIM Phase 2 trial evaluating the 2.4 mg dose of pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, in patients with moderate to severe AUD. The trial met its primary… Filing
- Jun 16, 2026AnnouncementAltimmune, Inc. announced plans to relocate its corporate headquarters from Gaithersburg, Maryland to Morristown, New Jersey later this year. Filing
- May 13, 2026ResultsReleased financial results. Filing
- Apr 24, 2026AgreementAltimmune, Inc. entered into an underwriting agreement with Leerink Partners LLC and Barclays Capital Inc., as representatives of the several underwriters named therein pursuant to which the Company agreed to issue and sell (i) 64,250,000 shares of the Company’s common stock, par value $0.0001 per… Filing
- Apr 16, 2026VoteReported shareholder vote results. Filing
- Mar 5, 2026ResultsReleased financial results. Filing
- Feb 3, 2026AnnouncementAltimmune, Inc. has established Thursday, April 16, 2026 as the date of the Company's 2026 Annual Meeting of Stockholders to align with the standard second quarter annual meeting calendar for companies operating on a 12/31 fiscal year-end. Filing
- Jan 28, 2026AgreementAltimmune, Inc. entered into a Securities Purchase Agreement with a new fundamental institutional investor relating to the issuance of 12,397,920 shares of the Company’s common stock, par value of $0.0001 per share and pre-funded warrants to purchase up to 4,647,534 shares of Common Stock (such… Filing
- Dec 19, 2025AnnouncementThe Company announced positive topline results from the IMPACT Phase 2b trial of pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, in patients with metabolic dysfunction-associated steatohepatitis at 48 weeks. Filing
- Dec 1, 2025LeadershipAltimmune, Inc. announced that, effective January 1, 2026, Vipin K. Garg, Ph.D. will transition from his role as President and Chief Executive Officer. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Altimmune financials
Famous investors that hold ALT
6 of the 50 well-known investors we track reported holding ALT in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $19.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Andreas Halvorsen · Viking Global Investors | Q3 2026 | 6.70M | $19.2M | 0.1% | No change |
| Israel Englander · Millennium Management | Q3 2026 | 3.84M | $11M | 0.0% | +16% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.46M | $4.2M | 0.0% | +200% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 693,769 | $2M | 0.0% | -29% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 108,146 | $309K | 0.0% | +51% |
| Jeremy Grantham · GMO | Q3 2026 | 35,659 | $102K | 0.0% | -57% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ALT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | TCG Crossover GP II, LLC | 13G/A | 2.5% |
| Nov 16, 2026 | TCG Crossover GP II, LLC | 13G/A | 2.5% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.3% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.3% |
Questions about Altimmune, Inc. (ALT) stock
Who owns the most ALT stock?
The largest reported owner of Altimmune, Inc. (ALT) is BlackRock, Inc., with 15.7% of the company. In total, 210 funds and institutions reported holding ALT at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are ALT insiders buying or selling?
In the last 12 months, ALT insiders reported 14 open-market purchases worth $452K and no sales. The latest trade was on Nov 13, 2026. See every trade.
What is the short interest in ALT?
As of Oct 30, 2026, 42.13M ALT shares were sold short, 21.7% of the shares outstanding, down 0.2% from the report before. At the average daily volume of 3.46M shares, buying them all back would take about 12.2 trading days (days to cover). See the history.
Which famous investors hold ALT?
6 of the 50 well-known investors we track reported ALT in their latest 13F filing, including Andreas Halvorsen, Israel Englander, Steve Cohen. The largest position is worth $19.2M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.